United Therapeutics to Take Lung-Drug Patent Fight to High Court

United Therapeutics Corp. plans to petition the US Supreme Court by June 10 to review its failed bid to revive a patent for its blockbuster lung-disease drug, Tyvaso, canceled by an administrative tribunal , according to a filing in Delaware federal court.

UTC urged Judge Richard G. Andrews to deny Liquidia Corp.'s request to remove part of his 2022 judgment blocking final approval of its rival drug, Yutrepia, according to a letter filed Wednesday in the US District Court for the District of Delaware. The filing argues Liquidia’s request is premature a day after the company touted a favorable Federal ...